



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

21st December 2023

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001.

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject and further to our intimation dated 8th September 2023, please find attached herewith the disclosure in accordance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl.: As above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/08/2023-24

Press Release

Hyderabad, 21st December 2023

LEGAL UPDATE

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) vide its disclosure dated 8th September 2023, has informed that Celgene Corporation, Bristol Myers Squibb Company, Breckenridge Pharmaceutical Inc. and Natco Pharma Limited have been named defendants in an antitrust lawsuit in the US by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc., regarding Pomalidomide (POMALYST) capsules.

The plaintiffs voluntarily dismissed Breckenridge Pharmaceutical Inc. and Natco Pharma Limited from the case. All claims against the Company in the litigation have now been dismissed.

Breckenridge is the ANDA holder and front-end marketing partner for the Pomalidomide capsules generic product in the US.

Natco's Pomalidomide capsules generic product has not yet launched in the US.

For NATCO Pharma Limited

Ch Venkat Ramesh
Company Secretary &
Compliance Officer